Jonathan Kimmelman

James McGill Professor, Biomedical Ethics Unit  / Social Studies of Medicine; cross appointments in Experimental Medicine

514-398-3306 | jonathan.kimmelman [at] | 3647 Peel, 306 | Twitter  

Kimmelman holds a PhD in Molecular Biophysics and Biochemistry from Yale, and is interim director of the Biomedical Ethics Unit. His research group, Studies in Translation Ethics and Medicine (STREAM), studies the ethics of human experimentation, drug development, and the medical encounter with uncertainty. Kimmelman has served on three U.S. National Academy of Medicine committees, and oversaw revisions to the International Society of Stem Cell Research Guidelines on Human Embryonic Stem Cell Research and Clinical Translation. His work is regularly featured in major media outlets. He received a Menten New Investigator Prize (2006) and a Humboldt Friedrich Bessel Award (2015).

Research Interests:

How are biological hypotheses transformed into validated therapies? How much patient burden is associated with developing a new drug- and are there avoidable inefficiencies in this process? To what extent can expert communities accurately predict major clinical advances in their field- and plan research accordingly? What constitutes an ethically sound basis for exposing patients to research risks like sham surgeries? My research group uses a mix of various empirical methods and conceptual analysis to address these and other questions relating to the moral dimensions of medical research. Further information on our team- and our various projects- can be found here.

Selected Publications:

Kimmelman J, Carlisle B, Gönen M. Drug Development at the Portfolio Level Is Important for Policy, Care Decisions and Human Protections. JAMA. August 2017

Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLOS Biology February 3, 2017.

Kimmelman J and Federico C. Consider drug efficacy before first-in-human trials. Nature 2017 January 31.

Benjamin D, Mandel DR, Kimmelman J. Can cancer researchers accurately judge whether preclinical reports will reproduce? PLOS Biology, June 2017; 15(6).

Hakala A, Fergusson D, Kimmelman J. Nonpublication of trial results for new neurological drugs: A systematic review. Annals of Neurology, 2017.

London AJ, Kimmelman J. Accelerated Drug Approval and Health Inequality. JAMA Intern Med. 2016. DOI:10.1001/jamainternmed.2016.2534.

Courses Given:

PHIL 643 / EPIB 625: Ethics of Human Experimentation

PIAT Selective: The ethics of human experimentation and clinical research” 

Lectures as part of medical curriculum: Conflict of interest

PDF icon cv_current_aug2017.pdf

Stay Connected

Back to top